Trial Profile
A Phase I Dose Escalation, Single Center, Open-Label Study of AUY922 Administered IV on a Once-Weekly Schedule in Adult Patients 75 Years of Age or Older With Advanced Solid Malignancies
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Luminespib (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Biomarker
- 24 May 2012 New trial record
- 01 Feb 2012 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.